India has also exported HCQ to more than 140 countries, Extreme Vardhan stated (File)
Re-purposed hydroxychloroquine is being used for moderate however high risk and moderate COVID-19 cases, Union Health Minister Harsh Vardhan said in Rajya Sabha on Tuesday.
According to the information shared by the minister, the Department of Pharmaceuticals has actually increased the production of hydroxychloroquine manifold and the health ministry has provided 10.84 crore tablets of the drug to states and union territories as on September 11.
” India has actually also exported it (hydroxychloroquine) to more than 140 nations,” Mr Vardhan stated.
He likewise stated there is a strategy to conduct trial of ayurvedic medications such as aswagandha, guduchi, pippali etc to avoid people from getting contaminated from COVID-19
The minister said no specific antivirals have actually been shown reliable so far and symptomatic treatment for fever and cough, proper rehydration, supplemental oxygen treatment stays the mainstay of treatment.
” We have actually re-purposed the drug hydroxychloroquine for mild (but high-risk cases) and for moderate cases. This was made with restricted clinical proof however well acknowledging that this drug has been used commonly in India for other conditions where it is utilized for extended amount of times, with great safety profile,” Mr Vardhan stated.
The government has likewise made arrangements for investigational treatments and has likewise been produced using Remdesivir, Convalescent plasma and Tocilizumab for managing extreme cases under close medical supervision, he said.
There are thirteen medical trials of repurposed drugs and harnessing of conventional understanding utilizing the modern medication approach are developing a portfolio of therapeutic choices for COVID-19 patients.
Phase 2 clinical trial of immunomodulator Sepsivac has been completed successfully and medical trial of the first-ever phytopharmaceutical ACQH is underway, the minister stated.
” One prophylactic trial of Aswagandha and 3 trials of Guduchi + Pippali; Yashtimadhu; and polyherbal AYUSH drug (AYUSH-64) are intended on moderately ill Covid19 clients,” he stated.
The minister said that more than 30 vaccine candidates have actually been supported which remain in different stages of advancement, 3 prospects remain in advanced stage of Phase I, II and III trials and more than 4 remain in advanced pre-clinical advancement phase in India.
Federal government action of nationwide lockdown, community participation etc has actually avoided up to 38 thousand deaths and 29 lakh COVID-19 cases in the country, the minister said.
He stated a total of 45,62,414 verified cases and 76,271 deaths have actually been reported in India out of which as numerous as 35,42,663 cases, 77.65 per cent of total, have actually recuperated.
” The optimum cases and deaths have actually been primarily reported from Maharashtra, Andhra Pradesh, Tamil Nadu, Karnataka, Uttar Pradesh, Delhi, West Bengal, Bihar, Telangana, Odisha, Assam, Kerala & Gujarat. All these States have actually reported more than one lakh cases,” Mr Vardhan stated.
He said that federal government efforts have actually been able to restrict its cases and deaths per million to 3,328 cases per 10 lakh and 55 deaths per 10 lakh population respectively, which is one of the most affordable on the planet as compared to similarly afflicted countries.
The minister notified Rajya Sabha that from a circumstance of a single lab geared up to undertake screening for COVID in January, currently 1705 laboratories are conducting COVID-19 Checking.
According to the minister, the COVID-19 test has actually reached 10 lakh checks a day which equates to 720 tests per 10 lakh population each day.
The main government has actually issued orders to purchase 60,948 ventilators to meet any contingencies and as on September 11, states have actually been designated 32,109 ventilators of which 30,170 have actually been delivered.
( Except for the headline, this story has actually not been edited by NDTV staff and is released from a syndicated feed.)